- Home
- LXRX
as 11-15-2024 4:00pm EST
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | THE WOODLANDS |
| Market Cap: | 650.7M | IPO Year: | 2000 |
| Target Price: | $6.00 | AVG Volume (30 days): | 4.3M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.97 - $3.73 | Next Earning Date: | 11-12-2024 |
| Revenue: | $5,229,000 | Revenue Growth: | 886.60% |
| Revenue Growth (this year): | 1212.46% | Revenue Growth (next year): | 219.10% |
Latest Lexicon Pharmaceuticals Inc. News
LXRX Breaking Stock News: Dive into LXRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
GuruFocus.com
4 days ago
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...
Zacks
4 days ago
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
4 days ago
Lexicon: Q3 Earnings Snapshot
GlobeNewswire
4 days ago
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
GuruFocus.com
6 days ago
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For
GlobeNewswire
11 days ago
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
Pharma Voice
11 days ago
A diabetes drug, twice rejected, stumbles again — but its developer persists
Compare LXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LXRX Lexicon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.